Published in J Hepatol on July 20, 2012
Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment. Dtsch Arztebl Int (2014) 2.21
Regular coffee: a magic bullet or a naked gun? Regular coffee but not espresso drinking is protective against fibrosis in NAFLD. J Hepatol (2013) 1.10
Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol (2014) 1.02
Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol (2014) 1.02
Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int (2013) 0.97
Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol (2016) 0.97
ER stress induces NLRP3 inflammasome activation and hepatocyte death. Cell Death Dis (2015) 0.95
Current concepts and management approaches in nonalcoholic fatty liver disease. ScientificWorldJournal (2013) 0.91
Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. Therap Adv Gastroenterol (2016) 0.90
Autophagy and non-alcoholic fatty liver disease. Biomed Res Int (2014) 0.87
I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. F1000Res (2015) 0.85
Coffee Consumption Decreases Risks for Hepatic Fibrosis and Cirrhosis: A Meta-Analysis. PLoS One (2015) 0.85
Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-analysis. Therap Adv Gastroenterol (2016) 0.84
Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug? Curr Neuropharmacol (2015) 0.78
Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease. World J Gastroenterol (2015) 0.77
Reply to: "regular coffee: a magic bullet or a naked gun? Regular coffee but not espresso drinking is protective against fibrosis in NAFLD". J Hepatol (2013) 0.77
A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterol Res Pract (2016) 0.77
Drinking coffee burns hepatic fat by inducing lipophagy coupled with mitochondrial β-oxidation. Hepatology (2014) 0.76
Coffee and Liver Disease. J Clin Exp Hepatol (2016) 0.75
Associations of coffee consumption with markers of liver injury in the insulin resistance atherosclerosis study. BMC Gastroenterol (2015) 0.75
Coffee: a panacea or snake oil for the liver? Clin Gastroenterol Hepatol (2014) 0.75
Coffee, caffeine and non-alcoholic fatty liver disease? Therap Adv Gastroenterol (2016) 0.75
Coffee: The magical bean for liver diseases. World J Hepatol (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology (2007) 3.75
Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology (2006) 3.09
Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem (2003) 2.38
M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology (2013) 2.16
Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol (2007) 2.08
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology (2006) 2.07
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology (2002) 2.06
Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology (2012) 2.01
Positioning trocars for performing sleeve gastrectomy. Points of controversy. Obes Surg (2015) 1.90
Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl (2006) 1.86
Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol (2006) 1.77
Single-port-access (SPA) cholecystectomy: a multi-institutional report of the first 297 cases. Surg Endosc (2010) 1.67
Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS (2004) 1.64
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol (2006) 1.58
CATSPER2, a human autosomal nonsyndromic male infertility gene. Eur J Hum Genet (2003) 1.54
C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. J Hepatol (2011) 1.54
Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol (2006) 1.49
Gastric pouch resizing for Roux-en-Y gastric bypass failure in patients with a dilated pouch. Surg Obes Relat Dis (2012) 1.49
KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol (2010) 1.48
Serum fibrosis markers can detect large oesophageal varices with a high accuracy. Eur J Gastroenterol Hepatol (2005) 1.47
HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer (2008) 1.44
Colonoscopic screening of first-degree relatives of patients with large adenomas: increased risk of colorectal tumors. Gastroenterology (2007) 1.44
The pig as a preclinical model for intestinal ischemia-reperfusion and transplantation studies. J Surg Res (2012) 1.44
Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children. J Pediatr Gastroenterol Nutr (2009) 1.44
Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One (2010) 1.44
Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients. Diabetes (2012) 1.42
The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH. Am J Gastroenterol (2006) 1.42
A national French survey on the use of growth factors as adjuvant treatment of chronic hepatitis C. Hepatology (2007) 1.39
Patients with acute liver failure listed for superurgent liver transplantation in France: reevaluation of the Clichy-Villejuif criteria. Liver Transpl (2015) 1.38
Unusual evolution of ciprofloxacin-induced hepatitis revealing a possible link with IgG4-associated autoimmune hepatitis. Dig Liver Dis (2011) 1.38
Internal hernia after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg (2006) 1.33
Congenital dyserythropoietic anemia type I is caused by mutations in codanin-1. Am J Hum Genet (2002) 1.32
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer (2004) 1.31
Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes (2008) 1.30
Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol (2011) 1.29
Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J Proteome Res (2010) 1.29
Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl (2005) 1.28
Matrix metalloproteinase inhibition protects rat livers from prolonged cold ischemia-warm reperfusion injury. Hepatology (2008) 1.27
The role of clips in preventing migration of fully covered metallic esophageal stents: a pilot comparative study. Surg Endosc (2011) 1.26
GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol (2011) 1.25
Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One (2009) 1.25
Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol (2005) 1.25
Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. J Med Virol (2004) 1.24
Laparoscopic repair of intrathoracic mesenterioaxial volvulus of the stomach in an adult: report of a case. Surg Today (2003) 1.23
Hepatitis E virus in HIV-infected patients. AIDS (2010) 1.19
Laparoscopic sleeve gastrectomy for morbid obesity. World J Gastroenterol (2008) 1.19
Palliative portal vein stent placement in malignant and symptomatic extrinsic portal vein stenosis or occlusion. Cardiovasc Intervent Radiol (2008) 1.19
The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease. PLoS One (2012) 1.17
Severe pneumonia during primary infection with an atypical strain of Toxoplasma gondii in an immunocompetent young man. J Infect (2005) 1.16
Expression of myotubularin by an adenoviral vector demonstrates its function as a phosphatidylinositol 3-phosphate [PtdIns(3)P] phosphatase in muscle cell lines: involvement of PtdIns(3)P in insulin-stimulated glucose transport. Mol Endocrinol (2003) 1.15
Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol (2006) 1.14
A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus. Eur J Gastroenterol Hepatol (2011) 1.12